XML 47 R27.htm IDEA: XBRL DOCUMENT v3.19.1
Summary of Significant Accounting Policies (Details Narrative)
$ in Thousands
12 Months Ended
Nov. 28, 2018
shares
Jan. 02, 2018
USD ($)
Dec. 31, 2018
USD ($)
Integer
shares
Dec. 31, 2017
USD ($)
shares
Dec. 31, 2011
Feb. 17, 2017
Dec. 31, 2016
USD ($)
Subsidiary, Sale of Stock [Line Items]              
Cash equivalents     $ 8,034 $ 7,600     $ 10,174
Available-for-sale securities, gross unrealized loss       527      
Common stock dividend     96        
Unrealized loss on marketable equity securities     (427)      
Proceeds from sale of common stock     10,000      
BioTime and AgeX Therapeutics shares held as marketable equity securities, at fair value     $ 400        
Estimated useful life of intangible assets     10 years   10 years    
Intangible assets noncash charge     $ 625        
Payment of interest and penalties            
Income tax rate     21.00% 34.00%      
Number of operating segment | Integer     1        
Minimum [Member]              
Subsidiary, Sale of Stock [Line Items]              
Estimated useful life of intangible assets     3 years        
Minimum [Member] | Equipment [Member]              
Subsidiary, Sale of Stock [Line Items]              
Estimated useful life of intangible assets     3 years        
Maximum [Member]              
Subsidiary, Sale of Stock [Line Items]              
Estimated useful life of intangible assets     10 years        
Maximum [Member] | Equipment [Member]              
Subsidiary, Sale of Stock [Line Items]              
Estimated useful life of intangible assets     5 years        
BioTime [Member]              
Subsidiary, Sale of Stock [Line Items]              
Number of shares received | shares 35,326            
Accounting Standards Update 2016-01 [Member]              
Subsidiary, Sale of Stock [Line Items]              
Available-for-sale securities, gross unrealized loss   $ 888          
BioTime, Inc. [Member]              
Subsidiary, Sale of Stock [Line Items]              
Equity ownership percentage           50.00% 51.10%
Number of shares sold during period | shares     266,442      
Realized loss on sale of BioTime shares       $ 309      
Shares held as available-for-sale securities, shares | shares     353,264        
BioTime and AgeX Therapeutics shares held as marketable equity securities, at fair value     $ 428        
Payment of interest and penalties            
AgeX Therapeutics, Inc [Member]              
Subsidiary, Sale of Stock [Line Items]              
Number of shares sold during period | shares 35,326            
Shares held as available-for-sale securities, shares | shares     35,326